PMN News | Roxom Stocks

1 BTC

- USD

Loading market data...

Mkt Cap

$74.7M

Volume

20.07K

Next Earnings

November 11th

Mkt Cap

$73.1M

Volume

20.07K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

ProMIS Neurosciences Reports Positive Blinded Six-Month Interim Safety and Biomarker Data for PMN310 in the PRECISE-AD Phase 1b Alzheimer’s Disease TrialProMIS Neurosciences announced positive interim results from its Phase 1b PRECISE-AD trial of PMN310, an experimental Alzheimer's disease treatment. The drug showed a favorable safety profile with no ARIA-E cases across all genotypes including high-risk APOE4 carriers, and demonstrated early biomarker movement consistent with target engagement. Full 12-month topline results are expected in Q1 2027.GlobeNewswire Inc. · Jul 28, 2026

ProMIS Neurosciences Reports First Human Evidence of Amyloid-Beta Oligomer Target Engagement by PMN310 at AAIC 2026ProMIS Neurosciences announced positive Phase 1a trial results showing PMN310, its lead Alzheimer's drug candidate, achieved dose-dependent reduction of amyloid-beta oligomers in human cerebrospinal fluid. The company demonstrated target engagement in healthy volunteers and plans to present six-month blinded interim data from its Phase 1b PRECISE-AD trial in the coming weeks, with top-line results expected in early Q1 2027.GlobeNewswire Inc. · Jul 14, 2026

ProMIS Neurosciences Announces Reverse Stock SplitProMIS Neurosciences is implementing a one-for-twenty-five reverse stock split to address Nasdaq listing requirements and potentially increase its stock price, reducing outstanding shares from approximately 53.8 million to 2.15 million.GlobeNewswire Inc. · Nov 24, 2025

ProMIS Neurosciences Announces Private Placement FinancingProMIS Neurosciences secured $3 million in private financing through a PIPE offering, with an additional $9 million from warrant exercises, totaling approximately $12 million in gross proceeds to advance clinical development of PMN310 and support corporate operations.GlobeNewswire Inc. · Jul 28, 2025

Alpha-Synuclein Inhibitors Clinical Trial Pipeline as Novel and Extensive 22+ Therapies Likely to Enter in the Domain | DelveInsightThe article discusses the growing pipeline of alpha-synuclein inhibitors, a class of investigational therapies targeting the aggregation of alpha-synuclein, a protein implicated in neurodegenerative diseases. The pipeline includes over 20 active players and 22+ pipeline therapies, with several promising candidates in various stages of clinical trials.GlobeNewswire Inc. · Feb 13, 2025

ProMIS Neurosciences Reports Positive Top-Line Data from its Phase 1a Alzheimer's TrialProMIS Neurosciences announced positive top-line data from the first four cohorts of its Phase 1a clinical trial of PMN310, an antibody therapeutic targeting toxic misfolded proteins in Alzheimer's disease. The data showed a favorable safety profile, dose-dependent levels of PMN310 in the cerebrospinal fluid, and potential for target engagement in Alzheimer's patients.GlobeNewswire Inc. · Jul 26, 2024

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent HighlightsTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024GlobeNewswire Inc. · May 14, 2024

Why Ultragenyx Pharmaceutical Shares Are Trading Lower By Around 9%? Here Are Other Stocks Moving In Monday's Mid-Day SessionShares of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) fell sharply during Monday’s session after the company revealed new data from the Phase 1/2 study of GTX-102 for Angelman syndrome, a genetic disorder causing developmental disabilities and nerve-related symptoms. Ultragenyx Pharmaceutical shares dipped 9.4% to $42.46 on Monday. Here are some other stocks moving in today's mid-day session. Gainers Soligenix, Inc. (NASDAQ: SNGX) shares surged 71.5% to $0.6679 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and post-exposure prophylaxis against MARV infection by the FDA. Longeveron Inc. (NASDAQ: LGVN) surged 54% to $2.6350 following insider buys from multiple company executives. SuperCom Ltd. (NASDAQ: SPCB) shares gained 39.4% to $0.3849 after jumping around 18% on Friday. Piedmont Lithium Inc. (NYSE: PLL) shares gained 32.1% to $16.75 following a 5% decline on Friday. Snap One Holdings Corp. (NASDAQ: SNPO) surged 31.6% to $10.71 after the company announced that it will be acquired by Resideo Technologies. Organovo Holdings, Inc. (NASDAQ: ONVO) shares surged 30.9% to $1.32 after the company announced Phase 2 results for FXR314. Study results demonstrated statistically significant reduction in liver fat content from baseline in patients receiving FXR314 compared to placebo. Kuke Music Holding Limited (NASDAQ: KUKE) jumped 27% to $2.7650. HUB Cyber Security Ltd. (NASDAQ: HUBC) gained 24% to $1.61 after gaining over 11% on Friday. Edgio, Inc. (NASDAQ: EGIO) gained 24% to $22.18. Kaival Brands Innovations Group, Inc. (NASDAQ: KAVL) ...Benzinga · Apr 15, 2024

Dow Jumps Over 300 Points; Goldman Sachs Posts Upbeat EarningsU.S. stocks traded higher this morning, with the Dow Jones index gaining more than 300 points on Monday. The Dow traded up 0.89% to 38,321.05 while the NASDAQ rose 0.70% to 16,288.03. The S&P 500 also rose, gaining, 0.80% to 5,164.30. Check This Out: Best Buy, Box And 2 Other Stocks Insiders Are Selling Leading and Lagging Sectors Financial shares jumped by 1.5% on Friday. In trading on Friday, real estate shares rose by just 0.3%. Top Headline Goldman Sachs Group Inc. (NYSE: GS) reported better-than-expected first-quarter earnings on Monday. Goldman Sachs reported revenue of $14.21 billion for the first quarter of 2024, beating the consensus of $12.92 billion. The U.S. financial services giant reported EPS of $11.58, beating the consensus of $8.60. Equities Trading UP Soligenix, Inc. (NASDAQ: SNGX) shares shot up 98% to $0.7699 after the company announced that it was granted orphan drug designation to the active ingredient in MarVax for the prevention and ...Benzinga · Apr 15, 2024

ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent HighlightsTop-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024 Top-line data from first-in-human Phase 1a clinical trial of PMN310 as a treatment for Alzheimer’s disease on track for mid-2024GlobeNewswire Inc. · Apr 1, 2024

PMNProMIS Neurosciences Inc. Common Shares (ON)

PMN

Pay with—

Start Trading

Available Balance0.00

Your PositionYou don't own any PMN yet.

Related Tickers

Earnings

Mkt Cap

$74.7M

Volume

20.07K

Next Earnings

November 11th